APREA THERAPEUTICS, INC.

(APRE)
  Report
Delayed Nasdaq  -  04:00 2022-08-12 pm EDT
0.9500 USD   -3.90%
08/12APREA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
08/11APREA THERAPEUTICS : Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations - Form 8-K
PU
08/11Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Berenberg Bank Adjusts Aprea Therapeutics' Price Target to $1 From $4, Maintains Hold Rating

05/25/2022 | 07:28am EDT


© MT Newswires 2022
All news about APREA THERAPEUTICS, INC.
08/12APREA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition a..
AQ
08/11APREA THERAPEUTICS : Reports Second Quarter 2022 Financial Results and Provides Update on ..
PU
08/11Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on..
GL
08/02APREA THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
08/02Aprea Therapeutics, Inc. Elects John B. Henneman III and Christian S. Schade as Directo..
CI
08/02Aprea Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Conference
GL
08/02Aprea Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Conference
AQ
07/29APREA THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing R..
AQ
07/08Top Premarket Gainers
MT
07/07Wedbush Initiates Aprea Therapeutics With Outperform Rating, $3 Price Target
MT
More news
Analyst Recommendations on APREA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -33,7 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,61x
Yield 2022 -
Capitalization 22,2 M 22,2 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees -
Free-Float 89,2%
Chart APREA THERAPEUTICS, INC.
Duration : Period :
Aprea Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends APREA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 0,95 $
Average target price 3,00 $
Spread / Average Target 216%
EPS Revisions
Managers and Directors
Oren Gilad President, Chief Executive Officer & Director
Scott M. Coiante Chief Financial Officer, Secretary & Senior VP
Christian S. Schade Chairman
Eyal C. Attar Chief Medical Officer & Senior Vice President
Lars Abrahmsén Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
APREA THERAPEUTICS, INC.-66.90%22
MODERNA, INC.-32.60%66 966
IQVIA HOLDINGS INC.-12.88%45 846
LONZA GROUP AG-25.13%44 851
SEAGEN INC.10.05%31 380
ALNYLAM PHARMACEUTICALS, INC.37.90%28 068